Guest guest Posted May 9, 2001 Report Share Posted May 9, 2001 : You mentioned being in Ohio- do you know any good doctors close to michigan? I am trying to locate one for my husband. He was diagnosed with PA about 3 years ago. he has a rheumatoid doctor locally (detroit area) but really hasn't had much luck with anything he's tried. He seems to be worse lately so i am trying to be more proactive in getting him to deal with it. He has a great attitude but sometimes it hinders him as he doesn't look for ways to alleviate his pain. Thanks in advance for your help! Quote Link to comment Share on other sites More sharing options...
Guest guest Posted May 11, 2001 Report Share Posted May 11, 2001 sorry...not familiar with your area....only know of doctors in ohio...columbus area....good luck and wishing your hubby a pain free day....MTNCAT Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 20, 2001 Report Share Posted June 20, 2001 Thanks, Claudine. Since I only take aleve on the rare ocassions I get a headache and my special aromatherapy cream doesn't work, I guess I don't need to worry. I suppose anything in extreme moderation would not cause damage....and fortunately I've not experienced the aches and pains that so many others have during treatment. I do have a bad back and plantar fascilia, but my accupuncturist takes care of them. claudine intexas wrote: > Aleve is a NSAID and does occasionally cause liver > problems, and kidney problems, just like all NSAID. > What my GI told me (and he is good) is that it is > pretty safe to take ANYTHING " IF " I am only going to > take it occasionally. Medication on a long-term, > frequent, or continuous basis is a whole different > story. Anyone who has HCV and who has low platelets > needs to be cautious with any NSAID since they all > increase the risk of bleeding, especially GI bleeds. > Here are the 'Warnings' with the prescribing > information on Aleve. (You can look up all the > prescribing info at http://www.rxlist.com/) > > WARNINGS > > Risk Of Gi Ulceration, Bleeding And Perforation With > Nsaid Therapy > > Serious GI toxicity such as bleeding, ulceration, and > perforation, can occur at any time, with or without > warning symptoms, in patients treated chronically with > NSAID therapy. Although minor upper GI problems, such > as dyspepsia, are common, usually developing early in > therapy, physicians should remain alert for > ulcerations and bleeding in patients treated > chronically with N.A.D. even in the absence of > previous GI tract symptoms. In patients observed in > clinical trials with naproxen of several months to two > years duration, symptomatic upper GI ulcers, gross > bleeding or perforation appear to occur in > approximately 1% of patients treated for 3-6 months, > and in about 2-4% of patients treated for one year. > Physicians should inform patients about the signs > and/or symptoms of serious GI toxicity and what steps > to take if they occur. > > Studies to date with all naproxen products have not > identified any subset of patients not at risk of > developing peptic ulceration and bleeding or any > differences between different naproxen products in > their propensity to cause peptic ulceration and > bleeding. Except for a prior history of serious GI > events and other risk factors known to be associated > with peptic ulcer disease, such as alcoholism, smoking > etc., no risk factors (e.g., age, sex) have been > associated with increased risk. Elderly or debilitated > patients seem to tolerate ulceration or bleeding less > well than other individuals and most spontaneous > reports of fatal GI events are in this population. > Studies to date are inconclusive concerning the > relative risk of various N.A.D. in causing such > reactions. High doses of any NSAID probably carry a > greater risk of these reactions, although controlled > clinical trials showing this do not exist in most > cases. In considering the use of relatively large > doses (within the recommended dosage range), > sufficient benefit should be anticipated to offset the > potential increased risk of GI toxicity. > > PRECAUTIONS > > General > > NAPRELAN SHOULD NOT BE USED CONCOMITANTLY WITH OTHER > NAPROXEN PRODUCTS SINCE THEY ALL CIRCULATE IN THE > PLASMA AS THE NAPROXEN ANION. > > The antipyretic and anti-inflammatory activities of > the drug may reduce fever and inflammation, thus > diminishing their utility as diagnostic signs. > > Because of adverse eye findings in animal studies with > drugs of this class, it is recommended that ophthalmic > studies be carried out if any change or disturbance in > vision occurs. > > Renal Effects > > As with other NSAIDs, long term administration of > naproxen to animals has resulted in renal papillary > necrosis and other abnormal renal pathology. In > humans, there have been reports of acute interstitial > nephritis, hematuria, proteinuria, and occasionally > nephrotic syndrome associated with naproxen-containing > products and other NSAIDs since they have been > marketed. > > A second form of renal toxicity has been seen in > patients taking naproxen as well as other NSAIDs. In > patients with prerenal conditions with reduction in > renal blood flow or blood volume, renal prostaglandins > have a supportive role in the maintenance of renal > perfusion. Administration of a NSAID may cause a > dose-dependent reduction in prostaglandin formation > and may precipitate overt renal decompensation. > Patients at greatest risk of this reaction are those > with impaired renal function, heart failure, liver > dysfunction, diuretic use, and the elderly. > Discontinuation of NSAID therapy is typically followed > by recovery to the pretreatment state. > > Naproxen and its metabolites are eliminated primarily > by the kidneys, therefore the drug should be used with > great caution in patients with significantly impaired > renal function and the monitoring of serum creatinine > and/or creatinine clearance is advised in these > patients. Caution should be used if the drug is given > to patients with creatinine clearance of less than 20 > mL/minute because accumulation of naproxen has been > seen in such patients. > > Hepatic Effects > > As with other NSAIDs, borderline elevations of one or > more liver tests may occur in up to 15% of patients. > These abnormalities may progress, may remain > essentially unchanged, or may resolve with continued > therapy. The ALT (SGPT) is probably the most sensitive > indicator of liver dysfunction. Meaningful (3 times > the upper limit of normal) elevations of ALT (SGPT) or > AST (SGOT) occurred in controlled clinical trials in > less than 1% of patients. A patient with symptoms > and/or signs suggesting liver dysfunction, or in whom > an abnormal liver test has occurred, should be > evaluated for evidence of the development of more > severe hepatic reaction while on therapy with > naproxen. Severe hepatic reactions, including jaundice > and cases of fatal hepatitis have been reported with > naproxen as with other NSAIDs. Although such reactions > are rare, if abnormal liver tests persist or worsen, > if clinical signs and symptoms consistent with liver > disease develop, or if systemic manifestations occur > (e.g. eosinophilia, rash, fever, etc.), naproxen > should be discontinued. Chronic alcoholic liver > disease and probably other diseases with decreased or > abnormal plasma proteins (albumin) reduce the total > plasma concentration of naproxen, but the plasma > concentration of unbound naproxen is increased. > Caution is advised when high doses are required and > some adjustment of dosage may be required in these > patients. It is prudent to use the lowest effective > dose. > > Fluid Retention and Edema > > Peripheral edema has been observed in some patients > receiving naproxen. Naprelan (naproxen sodium) tablets > contain 37.5 mg or 50 mg of sodium (1.5 mEq or 2.0 mEq > respectively). This should be considered in patients > whose overall intake of sodium must be severely > restricted. For these reasons, Naprelan should be used > with caution in patients with fluid retention, > hypertension or heart failure. > > Information For Patients > > Naprelan, like other drugs of its class, is not free > of side effects. This formulation of naproxen can > cause discomfort and rarely, there are more serious > side effects, such as GI bleeding, which may result in > hospitalization and even fatal outcomes. N.A.D. are > often essential agents in the management of arthritis > and have a major role in the treatment of pain but > they also may be commonly employed for conditions > which are less serious. Physicians may w.s. to discuss > with their patients the potential risks (see WARNINGS > and ADVERSE REACTIONS) and likely benefits of Naprelan > treatment. > > Caution should be exercised by patients whose > activities require alertness if they experience > drowsiness, dizziness, vertigo or depression during > therapy with naproxen. > > Laboratory Tests > > Because serious GI tract ulceration and bleeding can > occur without warning symptoms, physicians should > follow patients chronically treated with Naprelan for > the signs and symptoms of ulceration and bleeding, and > should inform them of the importance of this follow-up > and what they should do if certain signs and symptoms > do appear. Patients with initial hemoglobin values of > 10 grams or less who are to receive long-term therapy > should have hemoglobin values determined periodically. > (See WARNINGS—RISK OF GI ULCERATION, BLEEDING AND > PERFORATION WITH NSAID THERAPY). > > Drug Interactions > > See DRUG INTERACTIONS section. > > Drug/Laboratory Test Interactions > > Naproxen may decrease platelet aggregation and prolong > bleeding time. This effect should be kept in mind when > bleeding times are determined. The administration of > naproxen may result in increased urinary values for > 17-ketogenic steroids because of an interaction > between the drug and/or its metabolites with > m-dinitrobenzene used in this assay. Although > 17-hydroxy-corticosteroid measurements (Porter-Silber > test) do not appear to be artifactually altered, it is > suggested that therapy with naproxen be temporarily > discontinued 72 hours before adrenal function tests > are performed if the Porter-Silber test is to be used. > > Naproxen may interfere with some urinary assays of > 5-hydroxy indoleacetic acid (5HIAA). > > Carcinogenesis > > A two year study was performed in rats to evaluate the > carcinogenic potential of naproxen at doses of 8 > mg/kg/day, 16 mg/kg/day, and 24 mg/kg/day (50 mg/m2, > 100 mg/m2, and 150 mg/m2). The maximum dose used was > 0.28 times the systemic exposure to humans at the > recommended dose. No evidence of tumorigenicity was > found. > > Pregnancy > > Teratogenic Effects > > Pregnancy Category B: Reproduction studies have been > performed in rats at 20 mg/kg/day (125 mg/m2/day, 0.23 > times the human systemic exposure) rabbits at 20 > mg/kg/day (220 mg/m2/day, 0.27 times the human > systemic exposure) and mice at 170 mg/kg/day (510 > mg/m2/day, 0.28 times the human systemic exposure) > with no evidence of impaired fertility or harm to the > fetus due to the drug. There are no adequate and > well-controlled studies in pregnant women. Because > animal reproduction studies are not always predictive > of human response, Naprelan should be used during > pregnancy only if the potential benefits justify the > potential risks to the fetus. > > Nonteratogenic Effects > > There is some evidence to suggest that when inhibitors > of prostaglandin synthesis are used to delay preterm > labor there is an increased risk of neonatal > complications such as necrotizing enterocolitis, > patent ductus arteriosus, and intracranial hemorrhage. > Naproxen treatment given in the late pregnancy to > delay parturition has been associated with persistent > pulmonary hypertension, renal dysfunction, and > abnormal prostaglandin E levels in preterm infants. > Because of the known effect of drugs of this class on > the human fetal cardiovascular system (closure of > ductus arteriosus), use during third trimester should > be avoided. > > Nursing Mothers > > The naproxen anion has been found in the milk of > lactating women at a concentration of approximately 1% > of that found in the plasma. Because of the possible > adverse effects of prostaglandin-inhibiting drugs on > neonates, use in nursing mothers should be avoided. > > Pediatric Use > > No pediatric studies have been performed with > Naprelan, thus safety of Naprelan in pediatric > > > __________________________________________________ > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 20, 2001 Report Share Posted June 20, 2001 Thanks, Claudine. Since I only take aleve on the rare ocassions I get a headache and my special aromatherapy cream doesn't work, I guess I don't need to worry. I suppose anything in extreme moderation would not cause damage....and fortunately I've not experienced the aches and pains that so many others have during treatment. I do have a bad back and plantar fascilia, but my accupuncturist takes care of them. claudine intexas wrote: > Aleve is a NSAID and does occasionally cause liver > problems, and kidney problems, just like all NSAID. > What my GI told me (and he is good) is that it is > pretty safe to take ANYTHING " IF " I am only going to > take it occasionally. Medication on a long-term, > frequent, or continuous basis is a whole different > story. Anyone who has HCV and who has low platelets > needs to be cautious with any NSAID since they all > increase the risk of bleeding, especially GI bleeds. > Here are the 'Warnings' with the prescribing > information on Aleve. (You can look up all the > prescribing info at http://www.rxlist.com/) > > WARNINGS > > Risk Of Gi Ulceration, Bleeding And Perforation With > Nsaid Therapy > > Serious GI toxicity such as bleeding, ulceration, and > perforation, can occur at any time, with or without > warning symptoms, in patients treated chronically with > NSAID therapy. Although minor upper GI problems, such > as dyspepsia, are common, usually developing early in > therapy, physicians should remain alert for > ulcerations and bleeding in patients treated > chronically with N.A.D. even in the absence of > previous GI tract symptoms. In patients observed in > clinical trials with naproxen of several months to two > years duration, symptomatic upper GI ulcers, gross > bleeding or perforation appear to occur in > approximately 1% of patients treated for 3-6 months, > and in about 2-4% of patients treated for one year. > Physicians should inform patients about the signs > and/or symptoms of serious GI toxicity and what steps > to take if they occur. > > Studies to date with all naproxen products have not > identified any subset of patients not at risk of > developing peptic ulceration and bleeding or any > differences between different naproxen products in > their propensity to cause peptic ulceration and > bleeding. Except for a prior history of serious GI > events and other risk factors known to be associated > with peptic ulcer disease, such as alcoholism, smoking > etc., no risk factors (e.g., age, sex) have been > associated with increased risk. Elderly or debilitated > patients seem to tolerate ulceration or bleeding less > well than other individuals and most spontaneous > reports of fatal GI events are in this population. > Studies to date are inconclusive concerning the > relative risk of various N.A.D. in causing such > reactions. High doses of any NSAID probably carry a > greater risk of these reactions, although controlled > clinical trials showing this do not exist in most > cases. In considering the use of relatively large > doses (within the recommended dosage range), > sufficient benefit should be anticipated to offset the > potential increased risk of GI toxicity. > > PRECAUTIONS > > General > > NAPRELAN SHOULD NOT BE USED CONCOMITANTLY WITH OTHER > NAPROXEN PRODUCTS SINCE THEY ALL CIRCULATE IN THE > PLASMA AS THE NAPROXEN ANION. > > The antipyretic and anti-inflammatory activities of > the drug may reduce fever and inflammation, thus > diminishing their utility as diagnostic signs. > > Because of adverse eye findings in animal studies with > drugs of this class, it is recommended that ophthalmic > studies be carried out if any change or disturbance in > vision occurs. > > Renal Effects > > As with other NSAIDs, long term administration of > naproxen to animals has resulted in renal papillary > necrosis and other abnormal renal pathology. In > humans, there have been reports of acute interstitial > nephritis, hematuria, proteinuria, and occasionally > nephrotic syndrome associated with naproxen-containing > products and other NSAIDs since they have been > marketed. > > A second form of renal toxicity has been seen in > patients taking naproxen as well as other NSAIDs. In > patients with prerenal conditions with reduction in > renal blood flow or blood volume, renal prostaglandins > have a supportive role in the maintenance of renal > perfusion. Administration of a NSAID may cause a > dose-dependent reduction in prostaglandin formation > and may precipitate overt renal decompensation. > Patients at greatest risk of this reaction are those > with impaired renal function, heart failure, liver > dysfunction, diuretic use, and the elderly. > Discontinuation of NSAID therapy is typically followed > by recovery to the pretreatment state. > > Naproxen and its metabolites are eliminated primarily > by the kidneys, therefore the drug should be used with > great caution in patients with significantly impaired > renal function and the monitoring of serum creatinine > and/or creatinine clearance is advised in these > patients. Caution should be used if the drug is given > to patients with creatinine clearance of less than 20 > mL/minute because accumulation of naproxen has been > seen in such patients. > > Hepatic Effects > > As with other NSAIDs, borderline elevations of one or > more liver tests may occur in up to 15% of patients. > These abnormalities may progress, may remain > essentially unchanged, or may resolve with continued > therapy. The ALT (SGPT) is probably the most sensitive > indicator of liver dysfunction. Meaningful (3 times > the upper limit of normal) elevations of ALT (SGPT) or > AST (SGOT) occurred in controlled clinical trials in > less than 1% of patients. A patient with symptoms > and/or signs suggesting liver dysfunction, or in whom > an abnormal liver test has occurred, should be > evaluated for evidence of the development of more > severe hepatic reaction while on therapy with > naproxen. Severe hepatic reactions, including jaundice > and cases of fatal hepatitis have been reported with > naproxen as with other NSAIDs. Although such reactions > are rare, if abnormal liver tests persist or worsen, > if clinical signs and symptoms consistent with liver > disease develop, or if systemic manifestations occur > (e.g. eosinophilia, rash, fever, etc.), naproxen > should be discontinued. Chronic alcoholic liver > disease and probably other diseases with decreased or > abnormal plasma proteins (albumin) reduce the total > plasma concentration of naproxen, but the plasma > concentration of unbound naproxen is increased. > Caution is advised when high doses are required and > some adjustment of dosage may be required in these > patients. It is prudent to use the lowest effective > dose. > > Fluid Retention and Edema > > Peripheral edema has been observed in some patients > receiving naproxen. Naprelan (naproxen sodium) tablets > contain 37.5 mg or 50 mg of sodium (1.5 mEq or 2.0 mEq > respectively). This should be considered in patients > whose overall intake of sodium must be severely > restricted. For these reasons, Naprelan should be used > with caution in patients with fluid retention, > hypertension or heart failure. > > Information For Patients > > Naprelan, like other drugs of its class, is not free > of side effects. This formulation of naproxen can > cause discomfort and rarely, there are more serious > side effects, such as GI bleeding, which may result in > hospitalization and even fatal outcomes. N.A.D. are > often essential agents in the management of arthritis > and have a major role in the treatment of pain but > they also may be commonly employed for conditions > which are less serious. Physicians may w.s. to discuss > with their patients the potential risks (see WARNINGS > and ADVERSE REACTIONS) and likely benefits of Naprelan > treatment. > > Caution should be exercised by patients whose > activities require alertness if they experience > drowsiness, dizziness, vertigo or depression during > therapy with naproxen. > > Laboratory Tests > > Because serious GI tract ulceration and bleeding can > occur without warning symptoms, physicians should > follow patients chronically treated with Naprelan for > the signs and symptoms of ulceration and bleeding, and > should inform them of the importance of this follow-up > and what they should do if certain signs and symptoms > do appear. Patients with initial hemoglobin values of > 10 grams or less who are to receive long-term therapy > should have hemoglobin values determined periodically. > (See WARNINGS—RISK OF GI ULCERATION, BLEEDING AND > PERFORATION WITH NSAID THERAPY). > > Drug Interactions > > See DRUG INTERACTIONS section. > > Drug/Laboratory Test Interactions > > Naproxen may decrease platelet aggregation and prolong > bleeding time. This effect should be kept in mind when > bleeding times are determined. The administration of > naproxen may result in increased urinary values for > 17-ketogenic steroids because of an interaction > between the drug and/or its metabolites with > m-dinitrobenzene used in this assay. Although > 17-hydroxy-corticosteroid measurements (Porter-Silber > test) do not appear to be artifactually altered, it is > suggested that therapy with naproxen be temporarily > discontinued 72 hours before adrenal function tests > are performed if the Porter-Silber test is to be used. > > Naproxen may interfere with some urinary assays of > 5-hydroxy indoleacetic acid (5HIAA). > > Carcinogenesis > > A two year study was performed in rats to evaluate the > carcinogenic potential of naproxen at doses of 8 > mg/kg/day, 16 mg/kg/day, and 24 mg/kg/day (50 mg/m2, > 100 mg/m2, and 150 mg/m2). The maximum dose used was > 0.28 times the systemic exposure to humans at the > recommended dose. No evidence of tumorigenicity was > found. > > Pregnancy > > Teratogenic Effects > > Pregnancy Category B: Reproduction studies have been > performed in rats at 20 mg/kg/day (125 mg/m2/day, 0.23 > times the human systemic exposure) rabbits at 20 > mg/kg/day (220 mg/m2/day, 0.27 times the human > systemic exposure) and mice at 170 mg/kg/day (510 > mg/m2/day, 0.28 times the human systemic exposure) > with no evidence of impaired fertility or harm to the > fetus due to the drug. There are no adequate and > well-controlled studies in pregnant women. Because > animal reproduction studies are not always predictive > of human response, Naprelan should be used during > pregnancy only if the potential benefits justify the > potential risks to the fetus. > > Nonteratogenic Effects > > There is some evidence to suggest that when inhibitors > of prostaglandin synthesis are used to delay preterm > labor there is an increased risk of neonatal > complications such as necrotizing enterocolitis, > patent ductus arteriosus, and intracranial hemorrhage. > Naproxen treatment given in the late pregnancy to > delay parturition has been associated with persistent > pulmonary hypertension, renal dysfunction, and > abnormal prostaglandin E levels in preterm infants. > Because of the known effect of drugs of this class on > the human fetal cardiovascular system (closure of > ductus arteriosus), use during third trimester should > be avoided. > > Nursing Mothers > > The naproxen anion has been found in the milk of > lactating women at a concentration of approximately 1% > of that found in the plasma. Because of the possible > adverse effects of prostaglandin-inhibiting drugs on > neonates, use in nursing mothers should be avoided. > > Pediatric Use > > No pediatric studies have been performed with > Naprelan, thus safety of Naprelan in pediatric > > > __________________________________________________ > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 10, 2007 Report Share Posted September 10, 2007 thanks liz, it is short term. i got the small blue tablets. i took one with food and it was fine. i read the warning and panicked!!! At 04:14 PM 9/10/2007, you wrote: >Hi Diane, > >I'm taking aleve for a back problem and I had to try a couple different >sizes of the pills to find one that didn't give me heartburn. (Okay, >don't get the quick dissolving gelcaps - they are gigantic!) I ended up >using the red and yellow small gelcaps. And I take them just before >eating so the food will buffer them. You should be fine, especially >since your use will be short term. > >Liz in Bellevue, WA > > >Diane wrote: > > my doctor wants me to take aleve, to help reduce the inflammation > > from an infection in my ear ( from a piercing i got for my birthday) > > -- is that a problem? > > > > Diane B > > > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 11, 2007 Report Share Posted September 11, 2007 Hi, Diane - This is a question for your band surgeon. Most feel that 3- 4 days max of an NSAID is ok, but some do not. Be sure to cut it into small pieces, take with a full glass of fluid, and not within an hour of bedtime. Hope you're feeling fine again soon! Sandy R > > my doctor wants me to take aleve, to help reduce the inflammation > from an infection in my ear ( from a piercing i got for my birthday) > -- is that a problem? > > Diane B > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 30, 2008 Report Share Posted July 30, 2008 Here is the 411 on Aleve (naproxen): http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a681029.html One of the biggest health risks is gastrointestinal disorder, but if you are concerned you should ask your doctor why s/he asked you to stop taking it. RA North Jersey  Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 30, 2008 Report Share Posted July 30, 2008 Aleve is little more than an over-the-counter variation of naproxin, an NSAID. All of them carry the potential for gastro disorders, just as aspirin does. Anyone who takes them regularly over long periods of time risks the potential for developing serious health problems, including bleeding ulcers.  Joanna Hoelscher Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 31, 2008 Report Share Posted July 31, 2008 I only take Aleve maybe once a quarter, but took it daily during the first onset of my PA before I was prescribed Enbrel. While Aleve helped a bit, I seemed to get leg cramps (which is pain on top of pain when you have PA) when I would take it. Weird. " vdevera " <vdevera@...> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 31, 2008 Report Share Posted July 31, 2008 YES!!! My stomach hates me now for all the Aleve and Advil I took before I was put on prednisone and then MTX. I have an awful time with my stomach still after 5 years. prednisone is no picnic in the park either when it comes to left over side effects, but it was my LIFELINE for many months till the MTX took hold. Now I am having lung problems and have backed off the MTX, so I don't know what's next. I will be taking some pulmonary functions tests soon, and I see my rheumy next month. We'll see then. I am just happy the spot they found is an old scar (figures since I'm old) with calcium around it instead of a tumor or worse. Please take care you don't over-do those OTC NSAIDs, because they will do bad things to your stomach. God Bless, Janet in Ca Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 2, 2009 Report Share Posted July 2, 2009 Went to breast doctor...he told me to take Aleve 4 times a day...2 in am and 2 in pm...he said i have immflamation of the breast and muscle skelatal problems...my problem is since I have been taking...I feel worse...do you feel worse before you feel better or is this yet another thing I shouldn't be doing ? Thanks Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 3, 2009 Report Share Posted July 3, 2009 Hi , I'd be cautious with using any kind of pain reliever long term. My doc told me NOT to use them if at all possible. She said that anyone w/ inflammation is likely to have a sluggish liver. Many of the pain relievers such as Tylenol and Aleve have warnings saying do not use if you have kidney or liver damage. I know it's hard because you want instant relief but I think the best way to deal with inflammation is to clear it out through healthy diet and detox because a pain reliever doesn't get to the root cause...it just masks the symptoms for the moment and can end up making things worse if used too frequently. For more info see here. http://www.google.com/search?hl=en & q=aleve+liver+damage & aq=0 & oq=aleve+liver & aqi=g3 Good luck! PH >> Went to breast doctor...he told me to take Aleve 4 times a day...2 in am and 2 in pm...he said i have immflamation of the breast and muscle skelatal problems...my problem is since I have been taking...I feel worse...do you feel worse before you feel better or is this yet another thing I shouldn't be doing ? Thanks> Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.